Changes in Prescribing of Antiviral Medications for Influenza Associated With New Treatment Guidelines

Bibliographic Data

ID11033707
AuthorsAdam L Hersh (0000-0002-0148-046X, The authors are with the Division of General Pediatrics, University of California, San Francisco. Adam L. Hersh is also with the Division of Pediatric Infectious Diseases, Judith H. Maselli is also with the Department of Medicine, and Michael D. Cabana is also with the Philip R. Lee Institute for Health Policy Studies.), Judith H Maselli (The authors are with the Division of General Pediatrics, University of California, San Francisco. Adam L. Hersh is also with the Division of Pediatric Infectious Diseases, Judith H. Maselli is also with the Department of Medicine, and Michael D. Cabana is also with the Philip R. Lee Institute for Health Policy Studies.), Michael D Cabana (0000-0001-9376-2167, The authors are with the Division of General Pediatrics, University of California, San Francisco. Adam L. Hersh is also with the Division of Pediatric Infectious Diseases, Judith H. Maselli is also with the Department of Medicine, and Michael D. Cabana is also with the Philip R. Lee Institute for Health Policy Studies.)
Year2009
Volume99
IssueS2
PagesS362-S364
Publication date2009-10-01
Peer ReviewedYes
Open AccessNo
TypeARTICLE
VenueAmerican Journal of Public Health (JOURNAL)
Journal identifiersISSN: 0090-0036 • E-ISSN: 1541-0048
PublisherAmerican Public Health Association (PUBLISHER • US)
DOI10.2105/ajph.2009.171462
PMID19797750
PMCIDPMC4504359
OpenAlexW2064971407
LanguageEN
References cited2

In 2006, the Centers for Disease Control and Prevention recommended discontinuing the use of adamantanes (amantadine and rimantadine) to treat influenza because of high levels of resistance to this class of antivirals. We examined changes in prescribing practices resulting from this recommendation and found that prescribing of adamantanes declined nationwide, with these drugs accounting for approximately 40% of the antivirals prescribed for influenza from 2000 to 2005 and only 2% in 2006. This finding provides evidence of a rapid change in clinical practice associated with the dissemination of treatment guidelines. Evaluating the effectiveness with which public health recommendations are translated into practice is important given the ongoing emergence of resistance to antiviral drugs and a novel H1N1 influenza virus

Amantadine · Coronavirus disease 2019 (COVID-19) · Disease · Family medicine · Infectious disease (medical specialty) · Influenza A virus · Intensive care medicine · Pandemic · Public health · Rimantadine · Virus · Influenza Virus Research Studies · Internal Medicine · Medicine · School Health and Nursing Education · Smoking Behavior and Cessation · Virology

Tools

Open DOISci-HubOpen Access